Objective:To analyze expression of breast cancer suscepbility gene 2(BRCA2) in ovarian cancer tissues and its clinical significance. Methods:BRCA2 was detected using a pair of primer on 14 exon of BRCA2 by polymerase chain reaction amplification,and the mutations of BRCA2 were analyzed by DNA sequencing. The expression of BRCA2 protein in ovarian tumor tissues were detected by immunohistochemistry and Western blot. Results:No mutation was found in any mucinous cystadenoma and normal tissues,but the base T of 128 mutated C in 14 exon of BRCA2 in serous tumors and mucinous carcinoma. Western blot showed that BRCA2 protein expression of the malignant tumor in ovarian was lower than that of normal tissues and benign tumors. The results of immunohistochemistry showed that the BRCA2 expression rates in mucinous cystadenoma and mucinous carcinoma were 87.50% and 53.33% respectively,and there were significant differences between the mucinous cystadenoma and mucinous carcinoma (P < 0.05);whereas the BRCA2 expression rates in serous cystadenoma and serous carcinoma were 53.85% and 73.17% respectively,and there was no significant difference between the serous cystadenoma and serous carcinoma(P > 0.05). The BRCA2 expression was not significantly associated with patient’s age,clinical stage,differentiation and histological types of ovarian cancer (P > 0.05). Conclusion:BRCA2 expression in ovarian tumor tissues can be used as a diagnosis marker,it also may provide a target for the ovarian cancer treatment.